Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 30, 2024

https://www.globenewswire.com/news-release/2024/05/30/2890648/0/en/Patient-dosing-commenced-in-RePOSA-Phase-2-3-Clinical-Trial-Protocol-to-Assess-IHL-42X-Drug-in-Patients-with-Obstructive-Sleep-Apnea.html

NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq:IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea (‘OSA’).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.